Synchron
Synchron is an Endovascular BCI company founded in 2012 and based in Brooklyn, United States. It has raised $325M in total funding, most recently a Series D in 2025.
Delivers a motor neuroprosthesis via the jugular vein into brain blood vessels, avoiding open brain surgery. Stentrode system implanted in multiple patients in U.S. and Australia. Raised $200M Series D in November 2025, bringing total funding to $345M.
First to receive FDA Breakthrough Device designation for a permanently implantable BCI and first to implant a patient in the U.S., defining the minimally-invasive endovascular category.
At a glance
Total raised
$325M
Headcount
51-200
Headquarters
Brooklyn
United StatesFounded
2012
Status
Private
Subsector
Where Synchron ranks
Top 25 Brain-Computer Interfaces companies →Funding history
Total raised
$325M
Rounds tracked
4
Latest stage
Series D
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Nov 6, 2025 | Series D | $200M | — | Double Point Ventures |
| Dec 15, 2022 | Series C | $75M | — | ARCH Venture Partners |
